AltamarCAM Partners has acquired a 26% stake in Labomar, an Italian nutraceutical and cosmetics manufacturer, replacing several family offices and partnering with Cleon Capital. The deal signals growing private equity interest in the medical aesthetics supply chain, particularly in companies that combine cosmetics, dietary supplements, and medical devices under one roof. For overseas buyers and distributors, Labomar’s scale and M&A-driven growth model may offer new sourcing opportunities in Europe.
Deal structure and investors
AltamarCAM, a Spanish private markets manager with approximately €22 billion in committed capital, has acquired a minority stake from family offices that had been in Labomar’s capital since 2020. The investment also includes fresh capital to support Labomar’s ongoing M&A strategy. Cleon Capital, which entered Labomar in 2020 and was the anchor investor for its IPO, remains a co-investor. In 2023, British fund Chaterhouse led the delisting of Labomar from the stock exchange.
Labomar’s business and market position
:format(jpg)/f.elconfidencial.com%2Foriginal%2F57a%2F508%2F395%2F57a50839584f68357b93e36447576c77.jpg)
Founded in 1998 by CEO Walter Bertin, Labomar specializes in nutraceutical solutions, including cosmetics, dietary supplements, medical devices, and foods for special medical purposes, along with associated R&D. The company reported €140 million in revenue and €27 million in EBITDA in 2025. It has a strong presence in Italy and Spain, following the 2024 acquisition of Laboratorios Entema. Over the past five years, Labomar has tripled its sales, driven by a buy-and-build strategy.
Sourcing context for buyers
For importers and distributors of aesthetic devices, injectables, and skincare OEM products, Labomar’s expanded capabilities in nutraceutical and medical device manufacturing could provide a reliable European supply base. The company’s integrated R&D and production model may appeal to clinics and brands seeking customized formulations or co-manufacturing partnerships. The fresh capital injection is expected to accelerate further acquisitions, potentially broadening Labomar’s product portfolio and geographic reach.
:format(jpg)/f.elconfidencial.com%2Foriginal%2Fdcb%2Fe3d%2Fe79%2Fdcbe3de79e001323c7e269d0c2262b0d.jpg)
What buyers should watch
Overseas buyers should monitor Labomar’s post-deal M&A pipeline, as additional acquisitions could introduce new product categories or manufacturing capacities relevant to the medical aesthetics market. The involvement of AltamarCAM, now backed by Marsh through Mercer, adds financial stability and may facilitate cross-border distribution partnerships. Distributors in Asia and the Americas may find Labomar a strategic partner for European-sourced nutraceutical and aesthetic product lines.
Source: Read the original report | Published: June 16, 2026